Floatz logo

OFRANERGENE OBADENOVEC

Colorectal Cancer With Hepatic Metastases

National Cancer Institute (NCI)gene_therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Colorectal Cancer With Hepatic Metastases cohort.

Asset / SponsorPhaseRating
Floxuridine
National Cancer Institute (NCI)
Phase 2B
vg2025
Akeso
Phase 1/2CCC
Tkm-080301
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

OFRANERGENE OBADENOVEC is also rated in:

ovarian cancerDormant
B
Indicative ·
61 / 100
View asset →
glioblastomaDormant
B
Indicative ·
56 / 100
View asset →
colorectal neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →